Acute Kidney Injury

	11.17.2009 SPEAKER: Vishal S. Vaidya, PhD, Assistant Professor of Medicine, Harvard Medical School, Renal Division of Brigham and Women’s Hospital MODERATOR: Jeffrey Borenstein, PhD, Distinguished Member of the Technical Staff at the Charles Stark Draper Laboratory; Co-Program Leader, Tissue Engineering, CIMIT Video not available.

SHARE THIS PAGE:	- Email to a friend or add this page to a website.

Forum Abstract

Kidney disease is a major public health concern associated with a significantly high mortality. For over a century we have relied on serum creatinine (SCr) and blood urea nitrogen (BUN) as biomarkers to detect kidney injury but it is widely recognized that these functional markers are insensitive, nonspecific, and delayed indicators of kidney damage. In 2008, the United States Food and Drug Administration and European Medicines Agency qualified seven novel urinary biomarkers, including kidney injury molecule-1 (Kim-1), to monitor drug-induced kidney injury in preclinical studies and on a case-by-case basis in clinical trials. Vishal Vaidya’s lab showed that Kim-1 not only outperformed the conventional markers such as BUN, SCr but did so by achieving a receiver operator characteristics-area under the curve of 0.91–0.99, the highest performing biomarker of all those that have been examined to date. To facilitate the detection of Kim-1 Dr. Vaidya’s lab recently developed and evaluated a point of care assay that serves as a convenient, quick, and clear ‘yes or no’ diagnostic assay for early detection of kidney damage.

Post a Comment